Gamble Jones Investment Counsel Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)

Gamble Jones Investment Counsel decreased its holdings in Pfizer Inc. (NYSE:PFE) by 2.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 294,982 shares of the biopharmaceutical company’s stock after selling 5,867 shares during the quarter. Pfizer comprises approximately 1.1% of Gamble Jones Investment Counsel’s portfolio, making the stock its 23rd biggest position. Gamble Jones Investment Counsel’s holdings in Pfizer were worth $12,779,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Weybosset Research & Management LLC raised its position in shares of Pfizer by 2.0% in the 2nd quarter. Weybosset Research & Management LLC now owns 12,847 shares of the biopharmaceutical company’s stock worth $557,000 after purchasing an additional 250 shares during the last quarter. Financial Gravity Wealth Inc. raised its position in shares of Pfizer by 33.2% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 257 shares during the last quarter. Intl Fcstone Inc. raised its position in shares of Pfizer by 2.4% in the 2nd quarter. Intl Fcstone Inc. now owns 11,140 shares of the biopharmaceutical company’s stock worth $483,000 after purchasing an additional 261 shares during the last quarter. Lee Financial Co raised its position in shares of Pfizer by 6.2% in the 2nd quarter. Lee Financial Co now owns 4,569 shares of the biopharmaceutical company’s stock worth $198,000 after purchasing an additional 265 shares during the last quarter. Finally, Keystone Financial Group raised its position in shares of Pfizer by 1.8% in the 2nd quarter. Keystone Financial Group now owns 15,532 shares of the biopharmaceutical company’s stock worth $673,000 after purchasing an additional 278 shares during the last quarter. 71.68% of the stock is owned by institutional investors.

PFE has been the subject of several recent analyst reports. ValuEngine lowered Pfizer from a “hold” rating to a “sell” rating in a research report on Saturday, September 14th. JPMorgan Chase & Co. lifted their price target on Pfizer from $37.00 to $46.00 and gave the stock a “neutral” rating in a research report on Thursday, September 19th. They noted that the move was a valuation call. UBS Group reaffirmed a “neutral” rating and issued a $43.00 price target on shares of Pfizer in a research report on Monday, August 5th. Morgan Stanley lowered their price target on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 27th. Finally, Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 30th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $45.88.

In other news, major shareholder Pfizer Inc purchased 50,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $900,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Scott Gottlieb purchased 3,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average price of $34.72 per share, with a total value of $104,160.00. Following the completion of the purchase, the director now owns 3,000 shares in the company, valued at $104,160. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

NYSE PFE traded down $0.11 during trading hours on Monday, hitting $36.11. The company’s stock had a trading volume of 7,520,011 shares, compared to its average volume of 20,343,916. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $46.47. The company’s 50 day simple moving average is $35.82 and its two-hundred day simple moving average is $40.36. The company has a market cap of $197.90 billion, a P/E ratio of 12.04, a price-to-earnings-growth ratio of 2.84 and a beta of 0.65. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.75 by $0.05. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The company had revenue of $13.26 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the company earned $0.77 EPS. Pfizer’s revenue for the quarter was down 1.5% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.99%. Pfizer’s dividend payout ratio is currently 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: What is the price-to-earnings growth (PEG) ratio?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.